SV Life Sciences "exceeds target" in raising its fifth VC fund
This article was originally published in Scrip
The venture capital firm SV Life Sciences has completed the final closing of its newest fund, SV Life Sciences Fund V, with total commitments of more than $523 million, exceeding its target of $400 million.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.